Abstract

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)
B Douglas Smith ... Annie Guérin
Blood | VOL. 136
B Douglas Smith, et. al.B Douglas Smith ... Annie Guérin
05 Nov 2020
Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)
Kavita Sail ...
Blood | VOL. 136
Kavita Sail, et. al.Kavita Sail ...
05 Nov 2020
Characteristics and Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Receiving Venetoclax Combinations Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative
Catherine Lai ... Esprit Ma
Blood | VOL. 136
Catherine Lai, et. al.Catherine Lai ... Esprit Ma
05 Nov 2020
A Real-World Canadian Experience of Asciminib Use in Chronic Myeloid Leukemia (CML) Patients Who Failed Multiple Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
Anargyros Xenocostas ... Kareem Jamani
Blood | VOL. 138
Anargyros Xenocostas, et. al.Anargyros Xenocostas ... Kareem Jamani
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia.
Luisa Corrêa De Araujo Koury ... Eduardo M Rego
Blood | VOL. -
Luisa Corrêa De Araujo Koury, et. al.Luisa Corrêa De Araujo Koury ... Eduardo M Rego
28 May 2024
Adaptation to ex vivo culture reduces human hematopoietic stem cell activity independently of cell cycle.
Carys S Johnson ... Elisa Laurenti
Blood | VOL. -
Carys S Johnson, et. al.Carys S Johnson ... Elisa Laurenti
28 May 2024
CD20-bispecific antibodies improve response to CD19-CAR T-cells in lymphoma in-vitro and CLL in-vivo models.
Berit J Brinkmann ... Sascha Dietrich
Blood | VOL. -
Berit J Brinkmann, et. al.Berit J Brinkmann ... Sascha Dietrich
28 May 2024
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Matthew J Frigault ... Marcela V Maus
Blood | VOL. -
Matthew J Frigault, et. al.Matthew J Frigault ... Marcela V Maus
23 May 2024
View more papers